Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Ionis Pharmaceuticals IncfiledCriticalBiogen Ma Inc
Publication of AR117329A1publicationCriticalpatent/AR117329A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporcionan pautas posológicas para oligonucleótidos antisentido que se dirigen a SOD1 y sales de estos. Las pautas posológicas se utilizan en el tratamiento de sujetos que tienen o se encuentran en riesgo de desarrollar esclerosis lateral amiotrófica.Dosage guidelines are provided for antisense oligonucleotides targeting SOD1 and salts thereof. Dosage guidelines are used in the treatment of subjects who have or are at risk of developing amyotrophic lateral sclerosis.
ARP190103660A2018-12-142019-12-13
COMPOSITIONS AND METHODS TO TREAT AND PREVENT AMYOTROPHIC LATERAL SCLEROSIS
AR117329A1
(en)
? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION UNDERSTANDING AN INHIBITOR OF THE PROTEIN OF TRANSFER OF ESTER CHOLESTERILE AND INHIBITORS OF HMG COA REDUCTASA.